# Contact TB-500 Blueprint: Editorial and Correction Inquiries

> Contact TB-500 Blueprint about the thymosin beta-4 and TB-500 editorial digest — corrections, citation questions, and source feedback. Not a clinic, not a vendor, not a prescription.

Editorial questions, citation corrections, and source feedback — send them here.

## Editorial inquiries

This is the contact panel for TB-500 Blueprint, an independent editorial digest of the thymosin beta-4 and TB-500 research record. Use the form for corrections, citation questions, or feedback on a source. If you believe a study is mischaracterized — especially a fragment-versus-parent attribution — tell us which panel and which citation, and we will check it against the original.

We do not provide medical or legal advice, we do not sell or supply any product, and we cannot answer requests for dosing, sourcing, or treatment. Those are outside what an editorial project does, and questions of that kind will not receive a substantive reply.

## What we can help with

Good uses of this form: pointing out a broken or mismatched reference link; flagging a number that does not match the cited study; asking which paper supports a specific claim; or suggesting a peer-reviewed source we have missed. We read every message in that category.

This form collects only what you type into it. We are an editorial publisher, not a clinic or a pharmacy, and there is no patient relationship implied by contacting us.

---

The TB-500 record inked panel by panel on blueprint stock — the Ac-LKKTETQ fragment stamped apart from the full-length thymosin beta-4 it is sold as, the empty human-trial panel left visible, and the FDA 503A status struck first; no clinic at the press and nothing here priced or dispensed.